4 targeted drugs for treatment of the Endometrial Carcinoma

Date:2023-04-17 Views: 764 Times

Endometrial cancer is a disease in which malignant (cancer) cells form in the tissues of the endometrium. Obesity and having metabolic syndrome may increase the risk of endometrial cancer. Taking tamoxifen for breast cancer or taking estrogen alone (without progesterone) can increase the risk of endometrial cancer.

Targeted therapy is used to treat many types of cancer, but it's still fairly new in the treatment of endometrial cancer. Only a few of these drugs are in use at this time. 


Bevacizumab is a monoclonal antibody that functions as an angiogenesis inhibitor. It works by slowing the growth of new blood vessels by inhibiting vascular endothelial growth factor A (VEGF-A), in other words anti–VEGF therapy. Bevacizumab was approved for medical use in the United States in 2004.

Approval Statushttps://www.cancer.gov/about-cancer/treatment/drugs/bevacizumab
Instructions for use:dosing, indications, interactions...etc.https://reference.medscape.com/drug/avastin-mvasi-bevacizumab-342257


Pembrolizumab is used for the treatment of advanced or recurrent endometrial carcinoma (a type of uterine cancer) that has specific genetic features or is not curable by surgery or radiation.

Approval Statushttps://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab
Instructions for use:dosing, indications, interactions...etc.https://reference.medscape.com/drug/keytruda-pembrolizumab-999962


Lenvatinib is used in combination with pembrolizumab for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation.

Approval Statushttps://www.lenvima.com/#:~:text=LENVIMA%C2%AE%20(lenvatinib)%20is%20a,radioactive%20iodine%20and%20is%20progressing.
Instructions for use:dosing, indications, interactions...etc.https://reference.medscape.com/drug/lenvima-lenvatinib-999994


On February 9, 2023, the Food and Drug Administration (FDA) approved dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.

Approval Statushttps://www.fda.gov/news-events/press-announcements/fda-approves-immunotherapy-endometrial-cancer-specific-biomarker
Instructions for use:dosing, indications, interactions...etc.https://medlineplus.gov/druginfo/meds/a621030.html

To get the most recent information, always consult a healthcare professional or the official websites of the respective drugs.